Rapid expression of COVID-19 proteins by transient expression in tobacco
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
In 2020 we suffered from a major global pandemic caused by the SARS-CoV-2 coronavirus. Efforts to contain the virus include the development of rapid tests and vaccines, which require a ready supply of viral proteins. Here we report the production of two SARS-CoV-2 proteins by transient transformation of tobacco, leading to high expression within three days, and subsequent purification of the intact proteins. Such efforts may help to develop testing resources to alleviate the major impacts of this global pandemic.
Article activity feed
-
SciScore for 10.1101/2020.12.29.424712: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources They were next incubated in primary antibody solution for 2 hours at room temperature (1:1000 anti-Strep, IBA Life Sciences, 1:10,000 anti-FLAG M2 monoclonal antibody, Sigma in 2% milk Tris – buffered saline, 0.1% Tween (TBST)), followed by three ten minutes washes in TBST. anti-Strepsuggested: Noneanti-FLAGsuggested: NoneThen, blots were incubated for 1 hour in the secondary antibody solution (ECL Anti-mouse conjugated to horseradish peroxidase, 1:10,000, GE in 2% milk), followed by three … SciScore for 10.1101/2020.12.29.424712: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources They were next incubated in primary antibody solution for 2 hours at room temperature (1:1000 anti-Strep, IBA Life Sciences, 1:10,000 anti-FLAG M2 monoclonal antibody, Sigma in 2% milk Tris – buffered saline, 0.1% Tween (TBST)), followed by three ten minutes washes in TBST. anti-Strepsuggested: Noneanti-FLAGsuggested: NoneThen, blots were incubated for 1 hour in the secondary antibody solution (ECL Anti-mouse conjugated to horseradish peroxidase, 1:10,000, GE in 2% milk), followed by three ten-minute washes in TBST. Anti-mousesuggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-